For external validation, we applied an adjusted risk stratification algorithm to the RIFASHORT modified intention-to-treat population. The easier-to-treat TB and moderately-harder-to-treat TB phenotypes were combined for this validation. The separation in the two risk groups is very clear in both the 6 M HRZE control and the 4 M high dose rifampin regimens.
